Trials / Completed
CompletedNCT06114251
Hepatitis B Virus Reactivation: a Cautionary Event After Liver Transplantation for Patients With Hepatocellular Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 920 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Highly active hepatitis B virus (HBV) is known to be associated with poor outcomes in patients with hepatocellular carcinoma (HCC). This study aims to investigate the relationship between HBV status and HCC recurrence after liver transplantation. The study retrospectively analyzed HCC patients undergoing liver transplantation in 2 centers between January 2015 and December 2020. We reviewed post-transplant HBV status and its association with outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Diagnosis of postoperative recurrence of liver cancer | HBV serological markers, such as hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA were monitored regularly. The alpha-fetoprotein (AFP) level was determined every 1-2 months. The ultrasound or computed tomography or magnetic resonance imaging was performed every 3-6 months in HCC patients who underwent liver transplantation. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2020-12-31
- Completion
- 2023-06-01
- First posted
- 2023-11-02
- Last updated
- 2023-11-02
Source: ClinicalTrials.gov record NCT06114251. Inclusion in this directory is not an endorsement.